https://doi.org/10.4081/btvb.2022.52
Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history
Submitted: 5 September 2022
Accepted: 20 October 2022
Published: 7 November 2022
Accepted: 20 October 2022
Abstract Views: 1681
PDF: 161
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
The year 1222 has traditionally been accepted as the University of Padua’s founding date. The University of Padua is a prestigious center for learning and research, and over the centuries, it has produced luminaries in the most significant disciplines, including medicine, law, philosophy, theology, literature, engineering, astronomy, physics, politics, and religion. The Studium of the teaching of Medicine began around 1250 with the establishment of the Collegium of Medical and Arts Doctors. The history of Medicine at Padua University is extraordinarily rich and counts on the contribution of masters such as Vesalius, Falloppia, Girolamo Fabrici d’Acquapendente, William Harvey, Vallisneri, Ramazzini, Morgagni and many others including Galileo Galilei himself. This year marks the 800th anniversary of the University of Padua, and to commemorate this historic event, the Editor has asked the three of us to summarize the university’s most significant contributions to the fields of hemostasis and thrombosis over the past eight decades. Among all, it should be mentioned the relevant contribution of Prof. Antonio Girolami, who was the founder of the group of Thrombosis and Hemostasis in Padua and one of the Italian and international leaders in the field of the diagnosis and treatment of congenital bleeding disorders. However, due to the large number of outstanding scientists and significant research conducted in these fields at Padua University, it was extremely difficult for us to provide a concise summary of the university’s numerous contributions. Eventually, we concluded that it would be more useful to share with the Readers the experiences we have had over the past several decades, focusing on specific aspects of our research, work, and life at Padua University, and attempting to highlight the aspects that we believe have contributed most to the advancement of knowledge in the fields of thrombosis and hemostasis. Therefore, three topics have been selected and presented separately in a narrative format as pieces of our lives and of the history of our university.
Prandoni P, Lensing AWA, Büller HR, et al. Failure of computerized impedance plethysmography in the management of clinically suspected deep-vein thrombosis. Thromb Haemost 1991;65:233-6.
DOI: https://doi.org/10.1055/s-0038-1647490
Lensing AWA, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989;320:342-5.
DOI: https://doi.org/10.1056/NEJM198902093200602
Cogo A, Lensing AWA, Koopman MMW, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. Br Med J 1998;316:17-20.
DOI: https://doi.org/10.1136/bmj.316.7124.17
Bernardi E, Prandoni P, Lensing AWA, et al. D-Dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. Br Med J 1998;317:1037-40.
DOI: https://doi.org/10.1136/bmj.317.7165.1037
Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 2008;300:1653-9.
DOI: https://doi.org/10.1001/jama.300.14.1653
Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol 2015;2:e474–80.
DOI: https://doi.org/10.1016/S2352-3026(15)00190-8
Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal-vein thrombosis. The Lancet 1992;339:441-5.
DOI: https://doi.org/10.1016/0140-6736(92)91054-C
Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
DOI: https://doi.org/10.1056/NEJM199603143341102
Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
DOI: https://doi.org/10.7326/0003-4819-125-1-199607010-00001
Prandoni P, Lensing AWA, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-60.
DOI: https://doi.org/10.7326/0003-4819-137-12-200212170-00008
Prandoni P, Lensing AWA, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
DOI: https://doi.org/10.1056/NEJM199210153271604
Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435-41.
DOI: https://doi.org/10.1056/NEJMoa022157
Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
DOI: https://doi.org/10.1182/blood-2002-01-0108
Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-9.
DOI: https://doi.org/10.1056/NEJM200107193450302
Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
DOI: https://doi.org/10.7326/0003-4819-139-1-200307010-00008
Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-22.
DOI: https://doi.org/10.1056/NEJMoa1700518
Girolami A, Pengo V, Cappellato G, et al. Antithrombin III Padua: a "new" congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Folia Haematol Int Mag Klin Morphol Blutforsch 1983;110:98-111.
Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869-74.
DOI: https://doi.org/10.1182/blood.V68.4.869.869
Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987;70:69-76.
DOI: https://doi.org/10.1182/blood.V70.1.69.bloodjournal70169
Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
DOI: https://doi.org/10.1056/NEJMoa032274
Campello E, Spiezia L, Adamo A, Simioni P. Thrombophilia, risk factors and prevention. Expert Rev Hematol 2019;12:147-58.
DOI: https://doi.org/10.1080/17474086.2019.1583555
Wojcik EG, Simioni P, d Berg M, et al. Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin. Thromb Haemost 1996;75:70-5.
DOI: https://doi.org/10.1055/s-0038-1650223
Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
DOI: https://doi.org/10.1038/369064a0
Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
DOI: https://doi.org/10.1182/blood.V88.10.3698.bloodjournal88103698
Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Eng J Med 1997;336:399-403.
DOI: https://doi.org/10.1056/NEJM199702063360602
Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999;94:3702-6.
Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.
DOI: https://doi.org/10.1055/s-0037-1614442
Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002;99:1938-42.
DOI: https://doi.org/10.1182/blood.V99.6.1938
Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002;100:2403-5.
DOI: https://doi.org/10.1182/blood-2002-04-1186
Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996;75:422-6
DOI: https://doi.org/10.1055/s-0038-1650290
Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005;106:2363-5.
DOI: https://doi.org/10.1182/blood-2005-04-1461
Simioni P, Kalafatis M, Millar DS, et al. Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. Blood 1996;88:2101-8.
DOI: https://doi.org/10.1182/blood.V88.6.2101.bloodjournal8862101
Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009;361:1671-5.
DOI: https://doi.org/10.1056/NEJMoa0904377
George LA. Hemophilia gene therapy: ushering in a new treatment paradigm? Hematology Am Soc Hematol Educ Program 2021;2021:226-33
DOI: https://doi.org/10.1182/hematology.2021000254
Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012;366:2390-6.
DOI: https://doi.org/10.1056/NEJMoa1201994
Bulato C, Radu CM, Campello E, et al. New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 2016;36:1022-9
DOI: https://doi.org/10.1161/ATVBAHA.115.306914
Simioni P, Cagnin S, Sartorello F, et al. Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. Blood 2021;137:2383-93
DOI: https://doi.org/10.1182/blood.2020008168
de la Morena-Barrio ME, Suchon P, Jacobsen EM et al. Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood 2022;140:140-51
DOI: https://doi.org/10.1182/blood.2021014708
How to Cite
Simioni, P., Pengo, V., & Prandoni, P. (2022). Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history. Bleeding, Thrombosis and Vascular Biology, 1(3). https://doi.org/10.4081/btvb.2022.52
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
